Wire Fox Terrier & Degenerative Myelopathy (SOD1): Why ~94% Carry the Risk Allele — and Why That Isn’t a Diagnosis

The short answer: A “genetically at-risk” SOD1 result for a Wire Fox Terrier is a risk factor, not a diagnosis — it tells you the dog carries two copies of the c.118G>A variant linked to Degenerative Myelopathy (DM), not that the dog has or will develop the disease. The Wire Fox Terrier has the highest reported risk-allele frequency of any breed studied (94% in Zeng et al. 2014), but that is an allele frequency, not a disease rate — penetrance is incomplete and age-dependent, and many aged at-risk dogs never show a single sign. DM is inherited in an autosomal-recessive pattern and can only be confirmed the hard way: by ruling out other spinal disease and, definitively, by post-mortem examination of the spinal cord. The real value of the test is planning — informing breeding decisions and helping you and your vet watch for early neurological change. There is no cure, but daily controlled physiotherapy has been shown to meaningfully extend quality time (Kathmann et al. 2006).

The 94% headline — and what the SOD1 variant actually does

SamMy sister’s Wire Fox Terrier just tested “at-risk” for DM — is the whole breed doomed?

Elena MarshNot at all — Zeng 2014 found 94% carry the allele, but that’s a carrying rate, not a sickness rate.

Degenerative Myelopathy is an adult-onset, progressively worsening disease of the spinal cord, typically appearing after about 8 years of age. It is often described as a canine analog of human amyotrophic lateral sclerosis (ALS). The genetic link was identified by Awano and colleagues in 2009, who traced the risk to a single-letter change in the SOD1 gene: variant c.118G>A, which swaps one amino acid in the protein (p.E40K, in exon 2). It is catalogued as OMIA:000263-9615.

The headline number comes from Zeng et al. 2014, who genotyped a large population across 65 breeds that each had at least 50 dogs sampled. Among all of them, the Wire Fox Terrier had the highest c.118A allele frequency of any breed: 94%. It is worth pausing on exactly what that means. An allele frequency describes how common a genetic variant is in the gene pool — not how many dogs get sick. A breed can be saturated with a risk allele and still have many, many dogs that live long lives without ever developing DM.

The SOD1 protein normally helps neutralize harmful oxidative by-products inside cells. The E40K change is thought to make the protein prone to misfolding and toxic aggregation in motor neurons — the same broad mechanism implicated in some inherited forms of human ALS. That is why the variant matters biologically, but biology at the molecular level does not translate into a guaranteed clinical outcome.

See Awano 2009 (https://pmc.ncbi.nlm.nih.gov/articles/PMC2634802/) and Zeng 2014 (https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.12317).

Risk versus diagnosis: incomplete penetrance explained

SamSo if my own dog is at-risk, does that basically confirm he’ll go down in his back legs someday?

Elena MarshNo — Awano 2009 documented aged at-risk dogs that never developed clinical signs; penetrance is incomplete.

This is the single most important idea to hold onto: an at-risk (A/A homozygous) result is a risk factor, not a diagnosis. DM in this SOD1 context follows an autosomal-recessive pattern with incomplete, age-dependent penetrance. “Recessive” means a dog generally needs two copies of the risk allele to be at appreciable genetic risk. “Incomplete penetrance” means that even among those two-copy dogs, not all go on to develop the disease. “Age-dependent” means the risk only becomes relevant late in life — a two-year-old at-risk dog is not a two-year-old with DM.

Awano and colleagues specifically observed older at-risk dogs that reached advanced age without clinical signs. That single fact should reframe how you read your report: the test is telling you about genetic predisposition within a population, not delivering a verdict about one individual animal’s future.

Because of incomplete penetrance, the responsible way to use an at-risk result is as a prompt: talk it through with your veterinarian, note the dog’s age, and agree on what early changes would be worth watching for — without assuming an outcome.

How DM is actually diagnosed — a diagnosis of exclusion

SamIf the DNA test can’t confirm it, how do vets ever actually diagnose DM?

Elena MarshIt’s a diagnosis of exclusion — clinicians rule out disc disease and tumors first, as the Cornell-linked literature describes.

Here is a claim worth stating plainly: the genetic test does not detect or confirm DM. It screens for a risk variant. Clinically, DM is a diagnosis of exclusion. Because its early signs — hind-limb weakness, wobbling, knuckling of the paws — overlap heavily with far more common and often treatable conditions, veterinarians must first rule those out.

The workup typically involves MRI or CT to look for disc herniation (IVDD), spinal tumors, or other compressive myelopathies, sometimes alongside cerebrospinal fluid (CSF) analysis. When those tests come back clean and the clinical picture fits, DM becomes the leading suspicion — but even then it remains a presumptive diagnosis in the living animal.

Definitive confirmation is only possible post-mortem, through histopathological examination of the spinal cord, which shows the characteristic degeneration. This is why no laboratory can honestly promise to “confirm DM” from a cheek swab. For context on the exclusion-based approach, see the Cornell-associated literature: https://pmc.ncbi.nlm.nih.gov/articles/PMC10472985/. The variant itself is documented at OMIA (https://omia.org/OMIA000263/9615/).

Clear, carrier, at-risk — what each genotype means for owners and breeders

SamMy report just says “carrier” — is that better or worse than “at-risk”?

Elena MarshA carrier has one copy and is at much lower personal risk under the recessive model Awano 2009 described, but it matters for breeding.

Most laboratories report three genotypes. Understanding them removes a lot of anxiety and turns the result into a practical planning tool rather than a scare.

For owners of a pet, the message is reassuring: a carrier result generally means very low personal risk, and even an at-risk result is a predisposition, not a sentence. Nothing about the result should change how much you love or exercise your dog day to day.

For breeders, the genetics matter more — precisely because the Wire Fox Terrier’s risk-allele frequency is so high (Zeng 2014). Removing every at-risk and carrier dog at once from a breed where 94% of the allele is present would collapse genetic diversity. The sustainable approach is gradual: test, then breed at-risk or carrier dogs only to Clear partners, which prevents producing new at-risk puppies while preserving the gene pool. Selection can then tighten over generations.

Living with the risk: physiotherapy evidence and supportive care

SamIf it ever does turn into DM, is there really nothing we can do but watch?

Elena MarshThere’s no cure, but Kathmann 2006 found intensive physiotherapy extended mean survival to about 255 days versus roughly 55 with none.

Let’s be honest and gentle at the same time: there is currently no cure and no disease-modifying treatment for DM. But “no cure” is not the same as “nothing helps.” The most encouraging evidence comes from Kathmann et al. 2006, who found that dogs receiving intensive, structured physiotherapy had a mean survival of about 255 days, compared with roughly 55 days in dogs that received no physiotherapy. That is a substantial difference in quality time, driven not by a drug but by disciplined daily care.

Practical supportive care centers on daily controlled physiotherapy and gentle, consistent exercise to maintain muscle and mobility for as long as possible. Alongside this, owners commonly use non-slip flooring, protective boots to guard knuckling paws, harnesses and slings for support, and — later in progression — mobility carts. Attentive nursing to prevent pressure sores and manage continence becomes important as the disease advances.

None of this reverses DM, and it is essential to work under veterinary guidance rather than to self-prescribe. But the practical takeaway is genuinely hopeful: for a dog who does develop DM, engaged, consistent physiotherapy is the single best-evidenced way to extend good time together (Kathmann 2006).

Frequently asked questions

Q. Does a 94% allele frequency mean my Wire Fox Terrier will get DM?
No. That is an allele frequency reported by Zeng et al. 2014 — a measure of how common the c.118A variant is in the breed’s gene pool — not a disease rate. Penetrance is incomplete and age-dependent, and many at-risk dogs never develop clinical signs (Awano 2009).

Q. Can the DNA test confirm that my dog has DM?
No. The test only screens for genetic risk. DM is a diagnosis of exclusion made by ruling out conditions like disc disease and tumors with MRI/CT and CSF analysis, and it can only be definitively confirmed by post-mortem examination of the spinal cord.

Q. My dog is a “carrier” — should I be worried about his health?
A carrier has just one copy of the variant and, under the recessive model described by Awano 2009, is at very low personal risk of developing DM. The carrier status mainly matters for breeding decisions, not for your pet’s day-to-day health.

Q. If my dog does develop DM, is there any treatment that helps?
There is no cure or disease-modifying drug, but supportive care makes a real difference. Kathmann et al. 2006 found that intensive physiotherapy extended mean survival to about 255 days, versus roughly 55 days with none — always pursued under veterinary guidance.

References

• Awano et al. 2009 (PNAS): https://pmc.ncbi.nlm.nih.gov/articles/PMC2634802/
• Zeng et al. 2014 (J Vet Intern Med): https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.12317
• Kathmann et al. 2006 (J Vet Intern Med): https://pubmed.ncbi.nlm.nih.gov/16955818/
• OMIA:000263-9615 (SOD1, DM in dog): https://omia.org/OMIA000263/9615/
• Diagnosis-of-exclusion context (Cornell-associated literature): https://pmc.ncbi.nlm.nih.gov/articles/PMC10472985/

About the author

Elena Marsh

Editor & writer (not a veterinarian)

A writer with a molecular-biology background and a lifelong dog and cat owner. Not a veterinarian — she translates peer-reviewed genetics research and primary data into plain language, always as information rather than diagnosis.